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Abstract: This paper reports on the successful management of hyperphagia (exaggerated hunger) in
a 14yr-old female with Prader–Willi syndrome (PWS). This child was diagnosed with PWS, (maternal
uniparental disomy) at 18 months due to developmental delay, hypertonia, weight gain and extreme
eating behaviour. Treatment of a supplement for appetite suppression commenced at 2 years of age.
This single-case records ingestion of an Indian cactus succulent Caralluma fimbriata extract (CFE) over
12 years, resulting in anecdotal satiety, free access to food and management of weight within normal
range. CFE was administered in a drink daily and dose was slowly escalated by observation for
appetite suppression. Rigorous testing determined blood count, vitamins, key minerals, HbA1c,
IGF-1 and function of the liver and thyroid all within normal range. The report suggests a strategy
for early intervention against hyperphagia and obesity in PWS. This case was the instigator of the
successful Australian PWS/CFE pilot and though anecdotal, the adolescent continues to ingest CFE
followed by paediatricians at the Royal Children’s Hospital Melbourne, Victoria, Australia. Future
clinical trials are worth considering, to determine an appropriate dose for individuals with PWS.
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1. Introduction
Prader-Willi syndrome (PWS) establishes a disrupted appetite with complex physical, behavioural
and intellectual issues at a prevalence of 1:15,000–1:30,000 [1,2]. The predominant difficulty in PWS is an
exaggerated appetite and a complex physiology which causes obesity. The hypothalamic dysfunction
in PWS may be similar to early onset obesity or hypothalamic obesity [3,4] however, in PWS the
disturbed neuroendocrine physiology is due to simultaneous non-functioning genes of the paternal
chromosome in the critical region 15q11.2–q13. In PWS the characteristic appetite phenotype is
established over three main phases [5] through: (1) ‘failure to thrive’ (newborn); (2a) increased weight
gain with minimal adjustment in caloric intake; (2b) increased interest in food and caloric intake with a
switch to hyperphagia at the median of 54 months and (3) the propensity to excessive eating (mean
age 8 years). Typically, hyperphagia includes an impaired satiety [6,7]. Similar to obesity reported
due to mutations in the PCSK1 gene [8], PWS establishes hypogonadotropic, hypogonadism and
growth deficits. However, in PWS the obsessional eating behaviours determines the PWS phenotype
to be life-threatening. Hypothalamic disruptions, the extent of which are unknown, interact with
physiological deficits including growth hormone deficiency. Hypotonicity also exacerbates obesity
propensity by making exercise and energy balance difficult. As in non-syndromic polygenic obesity,
low caloric intake is important; however, in PWS this is constant and life-long. A range of interventions
are necessary to correlate with each phase; however, to date there is no prescribed intervention
or treatment for the switch to hyperphagia. Research into appetite supplements is limited [9,10]
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and management guidelines suggest interventions of diet, exercise and supervised access to food.
This is difficult due to individualized anxiety and obsessional behaviours. Typically the most utilized
intervention is life-long familial limit setting and external food surveillance, which for many includes
locked environments [11,12].
Caralluma fimbriata extract (CFE)—the intervention—is well known in Ayurvedic medicine.
This shrub grows wild throughout India, Pakistan and Afghanistan [13] and has been ingested
for centuries amongst populations as a natural appetite suppressant or as a vegetable substitute
in times of famine [13,14]. It is reported that genetic deletion of small nucleolar RNA (SnoRNA)
including the snord116 and snord115 contribute to the hyperphagia in PWS [15–17]. One of the most
important recognized disruptions is within the hypothalamic pathways, which are disturbed due to
disrupted SnoRNA115/HBII-52 transcription known to interact with transcription of the serotonin
(5Hydroxytryptamine; 5-HT) 5-HT2c receptor. This receptor is involved in anorexigenic signalling
within hypothalamic appetite pathways of the central nervous system (CNS). Previously we reported
that an extract of Caralluma fimbriata (CFE) used as the intervention in this case study was involved in
enhancing 5-HT2c receptor activity in a PWS animal model [18]. This activity conforms to a model of
increased satiety.
This single-case reports on continued management of PWS hyperphagic behaviours for a
14 year-old female (M) who has exhibited appetite at the highest eating code level: 5 [5]. Unusually,
chronic administration of the natural supplement, CFE—a powdered cactus succulent extract—has
been successful in maintaining reduced interest in food and a normal weight, over a period of 12 years
in individuals.
2. Case Study
This single female case-study was one of twins (2004). M’s gestation was quiet compared to her
brother and the birth was at 37 weeks by a double breach caesarean to a polyhydramnios mother of
42years-old. Both twins recorded a high Apgar score of 8/10, though M was administered oxygen
straight after delivery. At 2 h M had multiple tonic-clonic seizures, was hypothermic, hypoglycaemic,
had divergent gaze, hyperflexia and clonus. She was transferred to intensive care. A magnetic resonance
imaging (MRI) determined the newborn had extra axial space in the brain. M was administered
phenobarbital for seizures and was nasogastric tube fed due to “failure to thrive”. The other twin
was jaundiced, placed in special care and was discharged at 5 days. M was transferred to special
care at 2 weeks and was discharged at 5 weeks still nasogastric tube fed. Even though the core
features of PWS were apparent, including small size, hypotonicity (low muscle tone) and an inability
to suck or swallow [19,20], chromosome analysis was only conducted to rule out common disorders.
An electroencephalogram (EEG) scan showed abnormal spike wave activity and awkward postures
were noted. The diagnosis was recorded at discharge as encephalopathy and suspected Cerebral Palsy,
until further investigations. After discharge the parents stopped both the seizure medication and tube
feeding at 8 weeks and M was fed by formula in an adapted bottle. No further tonic-clonic seizures
were seen however, absence seizures continued till 10 years.
The parents devised an intervention program from 4 months [21] and M’s feeding
became normalized at 9 months, weight gain was seen at 12 months, however unusually—for
encephalopathy—weight was recorded on the 90-percentile whilst height remained on the 3rd-percentile
on the general public early weight/height for age guidelines. Hunger was noticed and celebrated; due
to past difficulties at 14 months, however, M continued to eat past the amount of her twin brother.
Observed behaviours included exaggerated crying, tantrums and reddening of the face. The facial
reddening was perhaps due to unexplained seizures. As the parents were unaware of PWS, they
utilized the exaggerated hunger to help M ambulate. For example, food was placed on a coffee-table
and shifted around to help M weight-bare and walk. M would follow food with the table’s assistance.
When left to her own devices with food nearby, M would continue to eat and would not stop of her
own accord (video recordings on request).
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Diagnosis of PWS was made at 18 months due to M’s weight gain and eating behaviour. The genetic
female molecular karyotype showed one long continuous stretch of homozygosity (17.5 Mb) along
chromosome 15, suggestive of maternal uniparental disomy (UPD). Other typical identifying features
included small hands and feet, dysmorphic facial features, light skin pigmentation and severe
developmental delay. Non appetite related issues experienced by M were vision impairment,
deteriorating teeth, scoliosis, early puberty, repetitive questioning, skin picking until 12 years
and anxiety.
3. Treatment Methodology
At 29 months of age CFE was sourced by the parents. Careful dosage of the product Slimaluma
was considered by direct communication with the manufacturers. CFE was given for breakfast daily,
in tropical juice (to cover the organic taste) at half a capsule (250 mg). The treatment dose was raised
by 250 mg increments as necessitated by signals of reduced satiation. The commercially recommended
adult dose is 1000 mg/d to be taken at 2 × 500mg doses. In M’s case the full dose was taken at once and
after 12 years (Table 1) is 2000 mg/d. Further increases may no longer be available.
Table 1. Age and anthropometric measurements in single-case with Prader-Willi syndrome (PWS)
ingesting Caralluma fimbriata extract (CFE) . Anthropometric measurements behavioural indications of
hyperphagia and additional intervention/exercise, in a single case of a female with PWS ingesting CFE
over 12 years. The case begins as a newborn and ceases at 14 years and 4 months of age. Weight in
Kg—kilograms, height in cm—centimetres, nil—represents no intervention, dose in mg—milligrams,
per d—day.
Age Yr/Month Weight Kg Height Cm Dose Mg/d Food/Hyperphagia Indication Other Intervention
Birth 2.35 Unsure nil Failure to thrive Unable to suck Tube fed, phentobarbatal
2.3 months 3.7 55 nil Feeding slowly Take out nasogastric tube Feeding extremely slowly;adapted bottle
8 months 6.5 65 nil Normalised appetite Bottle fed Feeding slowly withadapted bottle
12 months 8.2 68 nil Normalised appetite Bottle fed and soft food Adapted bottle exerciseprogram
18 months 12 72 nil Increased hunger Obese and ambulatingafter food
Diet 100% home exercise
program
20 months 12.9 78 nil Eating constantly Obese, always hungryambulating after food DIAGNOSIS
2 years 12.5 82.5 nil Hyperphagia Obesity, tantrums aroundfood and always hungry
Diet 60% home exercise
program
2 years,
4 months 12 85 250 Satiated
Saying no to dinner and
leaving food on plate
Diet 60% home exercise
program
4 years,
11months 19 104 500
Access to food with
supervision
Saying no to dinner and
minimal asking for food.
Diet 60% home exercise
program
6 years,
6 months 23 112
NIL for
6 days
Ceased CFE
hyperphagia returned
after 1.5 days
Tantrums around food
after 1.5 days. Licking
empty plate
Diet 60% ballet once
weekly
6 years,
6 months 23 112 500
Hunger persisted 1
day
Confirmation of satiety
and interested in other
activities
Diet 60% ballet once
weekly
7 years,
1 month 23.5 114 750
Non-restricted with
supervision Both hunger and satiety
Diet 60% ballet once
weekly
7 years,
9 months 25 119 1000
Non-restricted with
supervision
Saying no to dinner and
minimal hunger.
Diet 60% ballet once
weekly
8 years,
8 months 29 124 1000
Non-restricted with
supervision Interested in food
Diet 60%, routine no
exercise
9 years,
7 months 30 126 1250
Non-restricted with
supervision
Forgetting to eat food
provided
Diet 60%, routine no
exercise
10 years,
1 months 34 128 1250
Non-restricted with
supervision
Minimal communication
of hunger.
Diet 60%, routine no
exercise
11 years,
8 months 37 129 1250
Non-restricted with
supervision
Minimal communication
of hunger and throws out
school treats.
Diet 60%, routine ballet
once weekly
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Table 1. Cont.
Age Yr/Month Weight Kg Height Cm Dose Mg/d Food/Hyperphagia Indication Other Intervention
12 years,
5 months 38 134 1500
Non-restricted with
supervision
Minimal communication
of hunger. Makes own
lunch.
Diet 60%, routine
swimming weekly
13 years,
1 month 39 136 1750
Non-restricted;
attempting no
supervision
Communication of both
hunger, “I’m hungry”,
and satiation “I’m full”.
Diet 60%, routine
swimming weekly
14 years,
4 months 43 141 2000
Non-restricted
environment.no
supervision
Communication hunger
and takes self out of
difficult situations.
Diet 60%, self-managed
swimming weekly
4. Results
During the earliest years of the intervention the child volunteered that “she felt full”, and
“was not hungry”, instead wanting to draw (video if requested). This was a significant adjustment
in comparison to recorded previous appetite behaviours, which were utilized as an instigator for
movement. From 2–4 years, satiety eventually reduced in increments noticed by an increased asking
for food. Each time this was observed the dose was increased by 250 mg/d. Within a day of increased
administration, decreased hunger was noted. The dose therefore followed a simple pattern: expressed
hunger, adjustment of dose and observed satiety. This process continued over 12 years with the most
recent 250 mg/d increase raising the dose to 2000 mg/d in 2018. Each time with the amount settled
upon there has been sustained successful appetite behaviour and freedom around food. All foods have
been allowed within the diet however, M has been educated on the nutritional and caloric values of
foods. It was noticed that M naturally initiates drinking a daily allowance of water (1 L/d).
Other medications administered were fluoxetine (LOVAN 20 mg, 9–14 years) for anxiety and
Growth Hormone Therapy. Though there is clear evidence to support Growth Hormone (GH) use in
PWS, it had been deemed that M was allergic to GH as after administration of a low dose of GH at
two timelines, M showed signs of an allergic reaction including fluid retention and dark, puffy eyes.
There is no known link to the intervention.
In 2010, M ceased taking the CFE extract for 6 days. Obvious changes to behaviour were recorded,
including, crying and tantrums due to food. These remonstrations were far stronger than that observed
by the parents when deciding to increase the dose. After 6 days the parents resumed administering CFE
and continued with a routine of a broad diet with restricted daily caloric intake to 60%. The indicators
of distress or hunger ceased within days and satiety resumed with M forgetting to eat after three days
of CFE intervention (videos of before and after available).
Interestingly, certain of M’s behaviours are not attenuated by CFE. These behaviours may be due
to anxiety and not hyperphagia, as they occur when M reports no hunger. These behaviours are: Skin
picking; asking and telling; feeding babies and animals and wanting to know the routine of the day.
These behaviours are moved-on easily during CFE administration.
Over the 12 years of administration there have been no adverse effects. The parents suggest
administration of savory salted foods increases focus after ingestion. Thirst for water may be an
unusual effect of CFE. Over the 12 years gastric emptying had not been an issue. In 2011 after 4 years
and 6 months administration of CFE, M was administered blood tests to determine any undue toxicity
or adverse effect due to CFE administration. The measures noted in Table 2, including kidney, thyroid
and liver function, blood count, IGF and HbA1C—measure of hyperglycaemia, were all within normal
range. Endocrine tests for central adrenal insufficiency (CAI) also recorded levels within normal range.
After 12 years, comprehensive blood tests determined M’s blood serum to be all within normal range
(Table 2) apart from the lowering of triglycerides.
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Table 2. Blood serum measures after 12 years of treatment Caralluma fimbriata extract (CFE) intervention.
Blood serum measures after 12 years of treatment CFE ingestion, in a single-case of a 14-year-old
female with Prader-Willi syndrome (PWS). IFCC - International Federation of Clinical Chemists; NGSP
- National Glycohemoglobin Standardization Program; Hct – haematocrit; RCC – red cell count; MCV
– mean corpuscular volume; MCH – haemoglobin devided by the number or red cells; RDW – red
blood cell width and distribution; EDTA as an anticoagulant, INR—international normalized ratio and
APTT—activated partial thromboplastin.
Specimen Type/Time 13:52 Serum Value Reference Range
25-OH Vitamin D 65 50–160 nmol/L
Vitamin A 1.2 0.9–2.5 µmol/L
Vitamin E 21 13–24 µmol/L
Calcium 2.27 2.10–2.60 nmol/L
Magnesium 0.70 0.70–1.20 nmol/L
Phosphate 1.45 1.10–1.80 nmol/L
Cholesterol 3.7 3.1–5.4 nmol/L
Triglyceride 0.8 (L) 0.9–2.0 mmol/L
Vitamin E/Lipid ratio 4.8 0.9–7.1 umol/mmol
Active Vitamin B12(Holotranscobalamin) 49.7 19–128 pmol/L
Ferritin 36 9–136 µg/L
Specimen type Whole Blood EDTA
HbA1c (IFCC) 31 26–39 mmol/mol
HbA1c (NGSP) 5.0 4.5–5.7%
Red Cell Folate 2925 1800–3700 µmol/L
Haemoglobin 122 120–160 g/L
Hct 0.36 0.36–0.46
RCC 4.00 4.0–5.2 × 10−12/L
MCV 90 78–97 fL
MCH 30.4 25–33 pg
RDW 12.5 11.0–14.0%
Platelets 197 150–400 × 10−9/L
White Cell Count 7.3 4.5–13.5 × 10−9/L
Neutrophils 4.22 1.8–8.0 × 10−9/L
Lymphocytes 2.59 1.2–5.2 × 10−9/L
Monocytes 0.42 0.1–1.0 × 10−9/L
Eosinophils 0.07 0.0–0.5 × 10−9/L
Basophils 0.02 0.0–0.1 × 10−9/L
Specimen Serum plasma
Zinc 9.5 9.2–15.4 µmol/L
Selenium 1.0 0.6–1.9 µmol/L
Thyroid stimulating hormone 2.96 0.50–4.50 mlU/L
Specimen Blood plasma
INR 1.1 0.8–1.2 ratio
APTT 34 27–44 s
Fibrinogen 2.4 1.5–4.3 g/L
Liver Function test Serum
Total Bilirubin 2 0–15 unmol/L
Unconjugated Bilirubin 2 0–10 unmol/L
Bilirubin 0 0–5 unmol/L
Neutrophils 26 10–30 IU/L
Lymphocytes 117 100–350 IU/L
Monocytes <10 0–40 IU/L
Eosinophils 72 57–80 g/L
Basophils 44 33–47 g/L
Urea, Creatinine & Electrolytes
Sodium 140 135–145 mmol/L
Potassium 4.2 3.5–5.0 mmol/L
Chloride 102 98–110 mmol/L
Urea 5.4 2.1–6.5 mmol/L
Creatinine 34 30–80 µmol/L
Weight reduced at the time of administration of CFE and had been stabilized to conform within
a normal range. M’s diet remained at a 60% ratio (of someone the same weight), though food with
lower sugar was preferable. Lipids seemed necessary within the diet to maintain homeostasis and
salt maintained alertness. Exercise was preferred, though due to GH allergy, M’s muscle tone did not
increase. Even so, M was active and energetic.
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5. Discussion
This study establishes a case for management of hyperphagia by daily CFE administration in
PWS. Over a 12-year-period hyperphagic behaviours have been contained without adverse effects in
one child/adolescent with PWS. The prediction of obesity [22] has also been halted by this family’s
management of dietary routine, exercise, supervision and CFE supplementation. The reduction of
food has been accepted with continual adjustment in dose of CFE. Further, the adolescent’s weight
has continued to decline over time. An important discussion point within this case-study is that
continued maintenance of weight reduction could need a dose escalation past 2000 mg/d. The parents
have chosen to longer increase the dose. Dose escalation has been gradual and though CFE is well
tolerated, it is inevitable that the dose may continue to escalate until BMI and adolescent growth stop
progressing. At this time, it has been confirmed that M’s growth is close to its ceiling, therefore the set
dose may not be a problem. Though CFE has been deemed safe by multiple safety assessments [23]
dose may be a limitation to this intervention’s capacity. Dose studies are necessary for a dose-weight
ratio to be established. In the past Victoria University has piloted a successful study of CFE treatment
in children and adolescents with PWS (n = 16), over a four-week period [10] —instigated by this
anecdotal evidence. Future study will need to include adults with established hyperphagia; obesity
and measures of glycaemic control would be preferable. Thirst may also be an important measure as
M’s instinct to drink is unusual for individuals with PWS.
Another point to consider is that the management of hyperphagic behaviours in PWS are quite
taxing on families. In M’s case her behaviours were similarly taxing during the 6 days without CFE in
2010, where vehement hunger was expressed. It is not clear if the hyperphagic distress experienced by
M over the short experimental cessation of CFE was her natural hyperphagia or a stronger hyperphagia
due to the years of satiety. Unfortunately, this connotes, anecdotally that there is no residual effect of
CFE over time.
6. Conclusions
In conclusion, this single-case determined that an extract of the Indian cactus succulent Caralluma
fimbriata eased hyperphagic over a 12-year-period. When the treatment was stopped for 6 days,
excessive hunger returned. Therefore, anecdotally CFE administration appears to create abstinence
from food within free access, leading to a routine natural cycle of appetite homeostasis, including
both hunger and satiety. Unfortunately, CFE does not create a residual effect and dose-weight ratios
must be defined to reduce confusion around dose adjustments to attenuate appetite behaviours. Even
though this family aimed for independence without supervision for their daughter, dose escalation
and phenotypical difficulties may have hindered this goal. This single-case study suggests that CFE
increases satiety and maintains weight overtime, within parameters of caloric restriction without
adverse effects or compromising blood serum measures.
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